1. Home
  2. CUE vs INO Comparison

CUE vs INO Comparison

Compare CUE & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

N/A

Current Price

$4.59

Market Cap

177.0M

Sector

Health Care

ML Signal

N/A

Logo Inovio Pharmaceuticals Inc.

INO

Inovio Pharmaceuticals Inc.

N/A

Current Price

$1.71

Market Cap

167.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CUE
INO
Founded
2014
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.0M
167.5M
IPO Year
2017
1999

Fundamental Metrics

Financial Performance
Metric
CUE
INO
Price
$4.59
$1.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
★ $68.67
$6.33
AVG Volume (30 Days)
552.6K
★ 18.9M
Earning Date
11-16-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 61.11
54.18
EPS
N/A
★ N/A
Revenue
$27,466,000.00
★ $42,220,086.00
Revenue This Year
N/A
$434.61
Revenue Next Year
N/A
$23,912.63
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 195.75
19.37
52 Week Low
$0.17
$0.56
52 Week High
$45.50
$2.72

Technical Indicators

Market Signals
Indicator
CUE
INO
Relative Strength Index (RSI) 24.71 63.16
Support Level $0.22 $1.08
Resistance Level $33.95 $1.94
Average True Range (ATR) 2.75 0.23
MACD -1.47 0.04
Stochastic Oscillator 8.18 63.18

Price Performance

Historical Comparison
CUE
INO

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

About INO Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Share on Social Networks: